{"database": "lobbying", "table": "lobbying_activities", "rows": [[963163, "4781f20d-1077-4e7b-bdd0-e275c4ae1e57", "Q2", "TARPLIN STRATEGIES LLC", 40032282, "GENENTECH, INC.", 2010, "second_quarter", "PHA", "Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit.\nH.R. 4213, the American Jobs, Closing Tax Loopholes and Preventing Outsourcing Act of 2010 - eligibility changes related to the 340B program, treatment of certain drugs for computation of Average Manufacturer's Price under the Medicaid program. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit.", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 75000, null, 0, 0, "2010-07-19T14:28:29.987000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["963163"], "units": {}, "query_ms": 25.21415997762233, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}